Verification of Low Risk for Perihippocampal Recurrence in Patients with Brain Metastases Who Received Whole-Brain Radiotherapy with Hippocampal Avoidance
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to analyze the patterns of failure and survival outcome in patients with brain metastases who received whole-brain radiotherapy (WBRT) with hippocampal avoidance (HA) using simultaneous integrated boost (SIB) on metastatic brain tumors. Materials and Methods We retrospectively reviewed 42 patients treated with HA-WBRT for brain metastases. A total of 25 Gy for whole brain and 35-55 Gy for gross tumors were delivered with 10 fractionations. Local tumor and intracranial progression were defined as a recurrence or tumor progression in SIB field and any recurrence or tumor progression within whole brain, respectively. Progression in HA zone was defined as the recurrence within the area expanded 5 mm from HA zone. Results Median follow-up duration was 10.0 months (range, 4.1 to 56.4 months). Intracranial progression was observed in 13 patients (31.0%) and the median duration from the start of HA-WBRT to progression was 10.6 months (range, 0.9 to 33.0 months). Local tumor progression and new metastasis outside SIB field occurred in 10 patients (23.8%) and nine patients (21.4%), respectively. There was no isolated hippocampal metastasis, except only one patient (2.4%) with multiple metastases inside and outside HA zone simultaneously. Median survival time and intracranial progression-free survival rate at 1 year were 19.4 months (95% confidence interval [CI], 9.6 to 29.2) and 71.5%, respectively, and those for overall survival were 26.5 months (95% CI, 15.4 to 37.5) and 67.9%, respectively. Conclusion HA-WBRT was associated with low risk of new metastasis in HA region in the patients with brain metastases. These findings would serve as useful guidance on applying HA-WBRT in clinical practice.
Abstract
Purpose The purpose of this study was to analyze the patterns of failure and survival outcome in patients with brain metastases who received whole-brain radiotherapy (WBRT) with hippocampal avoidance (HA) using simultaneous integrated boost (SIB) on metastatic brain tumors. Materials and Methods We retrospectively reviewed 42 patients treated with HA-WBRT for brain metastases. A total of 25 Gy for whole brain and 35-55 Gy for gross tumors were delivered with 10 fractionations. Local tumor and intracranial progression were defined as a recurrence or tumor progression in SIB field and any recurrence or tumor progression within whole brain, respectively. Progression in HA zone was defined as the recurrence within the area expanded 5 mm from HA zone. Results Median follow-up duration was 10.0 months (range, 4.1 to 56.4 months). Intracranial progression was observed in 13 patients (31.0%) and the median duration from the start of HA-WBRT to progression was 10.6 months (range, 0.9 to 33.0 months). Local tumor progression and new metastasis outside SIB field occurred in 10 patients (23.8%) and nine patients (21.4%), respectively. There was no isolated hippocampal metastasis, except only one patient (2.4%) with multiple metastases inside and outside HA zone simultaneously. Median survival time and intracranial progression-free survival rate at 1 year were 19.4 months (95% confidence interval [CI], 9.6 to 29.2) and 71.5%, respectively, and those for overall survival were 26.5 months (95% CI, 15.4 to 37.5) and 67.9%, respectively. Conclusion HA-WBRT was associated with low risk of new metastasis in HA region in the patients with brain metastases. These findings would serve as useful guidance on applying HA-WBRT in clinical practice.
참고문헌 (27)
- Khuntia D, "Whole-brain radiotherapy in the management of brain metastasis", J Clin Oncol, 24, pp.1295~1304 (2006)
- Diener-West M, "Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916", Int J Radiat Oncol Biol Phys, 16, pp.669~673 (1989)
- Gaspar LE, "The role of whole brain radiation therapy in the management of newly diagnosed brain metastases : a systematic review and evidence-based clinical practice guideline", J Neurooncol, 96, pp.17~32 (2010)
- Tsao MN, "Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es) : an American Society for Radiation Oncology evidence-based guideline", Pract Radiat Oncol, 2, pp.210~225 (2012)
- Chang EL, "Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial", Lancet Oncol, 10, pp.1037~1044 (2009)
- Patchell RA, "The management of brain metastases", Cancer Treat Rev, 29, pp.533~540 (2003)
- Patchell RA, "Postoperative radiotherapy in the treatment of single metastases to the brain : a randomized trial", JAMA, 280, pp.1485~1489 (1998)
- Soffietti R, "A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery : quality-of-life results", J Clin Oncol, 31, pp.65~72 (2013)
- Welzel G, "Memory function before and after whole brain radiotherapy in patients with and without brain metastases", Int J Radiat Oncol Biol Phys, 72, pp.1311~1318 (2008)
- Mizumatsu S, "Extreme sensitivity of adult neurogenesis to low doses of X-irradiation", Cancer Res, 63, pp.4021~4027 (2003)
- Monje ML, "Irradiation induces neural precursor-cell dysfunction", Nat Med, 8, pp.955~962 (2002)
- Nagai R, "Selective vulnerability to radiation in the hippocampal dentate granule cells", Surg Neurol, 53, pp.503~506 (2000)
- Gondi V, "Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy : safety profile for RTOG 0933", Radiother Oncol, 95, pp.327~331 (2010)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Sperduto PW, "A new prognostic index and comparison to three other indices for patients with brain metastases : an analysis of 1, 960 patients in the RTOG database", Int J Radiat Oncol Biol Phys, 70, pp.510~514 (2008)
- 김택균, "Epidemiology of Intracranial Metastases in Korea: A National Cohort Investigation", Cancer Research and Treatment, 50(1), pp.164~174 (2018), 대한암학회
- Andrews DW, "Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508randomised trial", Lancet, 363, pp.1665~1672 (2004)
- Kondziolka D, "Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases", Int J Radiat Oncol Biol Phys, 45, pp.427~434 (1999)
- Li J, "Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function", J Clin Oncol, 25, pp.1260~1266 (2007)
- Gondi V, "Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during wholebrain radiotherapy for brain metastases(RTOG 0933) : a phase II multi-institutional trial", J Clin Oncol, 32, pp.3810~3816 (2014)
- Harth S, "Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy", Radiother Oncol, 109, pp.152~158 (2013)
- Sun B, "Incidence and relapse risk of intracranial metastases within the perihippocampal region in 314 patients with breast cancer", Radiother Oncol, 118, pp.181~186 (2016)
- Hong AM, "Low incidence of melanoma brain metastasis in the hippocampus", Radiother Oncol, 111, pp.59~62 (2014)
- Oehlke O, "Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases : Local tumour control and survival", Strahlenther Onkol, 191, pp.461~469 (2015)
- Iuchi T, "Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFRmutant lung adenocarcinoma", Lung Cancer, 82, pp.282~287 (2013)
- Kim JE, "Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis", Lung Cancer, 65, pp.351~354 (2009)
- Park SJ, "Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation", Lung Cancer, 77, pp.556~560 (2012)